UK’s CMA Issues Fines Over Fludrocortisone
Amilco, Aspen And Tiofarma Named In UK Investigation
The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
You may also be interested in...
Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.